PMID- 33833800
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210410
IS  - 1687-8450 (Print)
IS  - 1687-8469 (Electronic)
IS  - 1687-8450 (Linking)
VI  - 2021
DP  - 2021
TI  - LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The 
      Therapy Opportunity in Tumor.
PG  - 5512524
LID - 10.1155/2021/5512524 [doi]
LID - 5512524
AB  - Tumors are the foremost cause of death worldwide. As a result of that, there has 
      been a significant enhancement in the investigation, treatment methods, and good 
      maintenance practices on cancer. However, the sensitivity and specificity of a 
      lot of tumor biomarkers are not adequate. Hence, it is of inordinate significance 
      to ascertain novel biomarkers to forecast the prognosis and therapy targets for 
      tumors. This review characterized LSD1 as a biomarker in different tumors. LSD1 
      inhibitors in clinical trials were also discussed. The recent pattern advocates 
      that LSD1 is engaged at sauce chromatin zones linking with complexes of 
      multi-protein having an exact DNA-binding transcription factor, establishing LSD1 
      as a favorable epigenetic target, and also gives a large selection of therapeutic 
      targets to treat different tumors. This review sturdily backing the oncogenic 
      probable of LSD1 in different tumors indicated that LSD1 levels can be used to 
      monitor and identify different tumors and can be a useful biomarker of 
      progression and fair diagnosis in tumor patients. The clinical trials showed that 
      inhibitors of LSD1 have growing evidence of clinical efficacy which is very 
      encouraging and promising. However, for some of the inhibitors such as 
      GSK2879552, though selective, potent, and effective, its disease control was poor 
      as the rate of adverse events (AEs) was high in tumor patients causing clinical 
      trial termination, and continuation could not be supported by the risk-benefit 
      profile. Therefore, we propose that, to attain excellent clinical results of 
      inhibitors of LSD1, much attention is required in designing appropriate dosing 
      regimens, developing in-depth in vitro/in vivo mechanistic works of LSD1 
      inhibitors, and developing inhibitors of LSD1 that are reversible, safe, potent, 
      and selective which may offer safer profiles.
CI  - Copyright (c) 2021 Clement Agboyibor et al.
FAU - Agboyibor, Clement
AU  - Agboyibor C
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
AD  - Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, 
      Zhengzhou 450001, China.
AD  - Key Laboratory of Advanced Technology of Drug Preparation Technologies (Zhengzhou 
      University), Ministry of Education of China, Zhengzhou 450001, China.
FAU - Dong, Jianshu
AU  - Dong J
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
AD  - Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, 
      Zhengzhou 450001, China.
AD  - Key Laboratory of Advanced Technology of Drug Preparation Technologies (Zhengzhou 
      University), Ministry of Education of China, Zhengzhou 450001, China.
FAU - Effah, Clement Yaw
AU  - Effah CY
AD  - College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
FAU - Drokow, Emmanuel Kwateng
AU  - Drokow EK
AD  - Department of Oncology, Zhengzhou University People's Hospital and Henan 
      Provincial People's Hospital Henan, Zhengzhou 450003, China.
FAU - Pervaiz, Waqar
AU  - Pervaiz W
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
AD  - Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, 
      Zhengzhou 450001, China.
AD  - Key Laboratory of Advanced Technology of Drug Preparation Technologies (Zhengzhou 
      University), Ministry of Education of China, Zhengzhou 450001, China.
FAU - Liu, Hong-Min
AU  - Liu HM
AUID- ORCID: 0000-0001-6771-9421
AD  - School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
AD  - Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, 
      Zhengzhou 450001, China.
AD  - Key Laboratory of Advanced Technology of Drug Preparation Technologies (Zhengzhou 
      University), Ministry of Education of China, Zhengzhou 450001, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210325
PL  - Egypt
TA  - J Oncol
JT  - Journal of oncology
JID - 101496537
PMC - PMC8018836
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/04/10 06:00
MHDA- 2021/04/10 06:01
PMCR- 2021/03/25
CRDT- 2021/04/09 06:26
PHST- 2021/01/21 00:00 [received]
PHST- 2021/03/04 00:00 [revised]
PHST- 2021/03/10 00:00 [accepted]
PHST- 2021/04/09 06:26 [entrez]
PHST- 2021/04/10 06:00 [pubmed]
PHST- 2021/04/10 06:01 [medline]
PHST- 2021/03/25 00:00 [pmc-release]
AID - 10.1155/2021/5512524 [doi]
PST - epublish
SO  - J Oncol. 2021 Mar 25;2021:5512524. doi: 10.1155/2021/5512524. eCollection 2021.